Skip to Main content Skip to Navigation
Journal articles

Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment

Abstract : Cladribine is an oral synthetic purine analog that depletes lymphocytes and induces a dose-dependent reduction of T and B cells. It was approved for the therapy of highly active relapsing-remitting multiple sclerosis. Given cladribine's mechanism of action, an increased risk of malignancies was suspected from the number of cancers that occurred in the 3.5 mg/kg-treated arm (CLARITY study). We showed that cladribine inhibits cell proliferation on three melanoma cell lines tested, irrespectively of their mutational oncogenic status and invasive/metastatic potential. Aggregated safety data demonstrated that the risk of melanoma is not confirmed.
Complete list of metadatas

Cited literature [9 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02914268
Contributor : Sophie Tartare-Deckert <>
Submitted on : Tuesday, August 11, 2020 - 3:12:46 PM
Last modification on : Wednesday, August 12, 2020 - 3:12:52 AM

File

Lebrun-Frenay2020_Article_Effe...
Publication funded by an institution

Identifiers

Collections

Citation

Christine Lebrun-Frenay, Ilona Berestjuk, Mikael Cohen, Sophie Tartare-Deckert. Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment. Neurology and Therapy, 2020, Online ahead of print. ⟨10.1007/s40120-020-00204-5⟩. ⟨inserm-02914268⟩

Share

Metrics

Record views

68

Files downloads

60